Correction to: European Journal of Clinical Microbiology & Infectious Diseases (2018) 37:2097–2106
The article “Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)”, written by Maria J. G. T. Vehreschild, Surabhi Taori, Simon D. Goldenberg, Florian Thalhammer, Emilio Bouza, Joop van Oene, Graham Wetherill, and Areti Georgopali, was originally published electronically on the publisher’s internet portal SpringerLink on 11 August 2018 without open access.
With the authors’ decision to opt for Open Choice the copyright of the article changed on October 2018 to © The Author(s) 2018 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at https://doi.org/10.1007/s10096-018-3344-1
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Vehreschild, M.J.G.T., Taori, S., Goldenberg, S.D. et al. Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE). Eur J Clin Microbiol Infect Dis 38, 199 (2019). https://doi.org/10.1007/s10096-018-3410-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-018-3410-8